Nuveen LLC Increases Stock Position in Abbott Laboratories $ABT

Nuveen LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,794,805 shares of the healthcare product maker’s stock after buying an additional 140,244 shares during the period. Nuveen LLC owned 0.68% of Abbott Laboratories worth $1,477,771,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares during the period. Capital International Investors grew its holdings in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. Capital Research Global Investors grew its holdings in shares of Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the period. Norges Bank purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth about $2,938,892,000. Finally, Invesco Ltd. grew its holdings in shares of Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott helped lead the first close of Star51 Capital’s inaugural medtech venture fund, highlighting its commitment to healthcare innovation and potential future deal flow in medtech. Star51 Capital Announces First Close of Medtech Venture Fund
• Positive Sentiment: Abbott received more support for its diabetes and cancer diagnostics growth story, including CE Mark approval for Libre Duo and updated colorectal cancer screening guidance favoring its tests, which could support long-term revenue growth. Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness
• Positive Sentiment: Abbott’s expanded agreement with MiniMed to commercialize dual glucose-ketone sensors adds another growth avenue in diabetes care and strengthens its connected-device strategy. This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In
• Neutral Sentiment: ABBT was noted as a trending stock on Zacks, suggesting elevated investor attention but not a clear fundamental catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analysts on balance were slightly more cautious, with Erste Group trimming its FY2027 EPS estimate only marginally to $6.04 from $6.05, a small change that does not signal a major shift in outlook. Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT)
• Negative Sentiment: Some investors also pointed to weakness in the stock itself, with recent trading showing ABT underperforming the broader market, suggesting sentiment remains pressured despite the positive product news. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Evercore decreased their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. decreased their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Argus decreased their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Bank of America decreased their target price on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.09.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $89.65 on Friday. The stock’s 50 day moving average price is $91.75 and its 200 day moving average price is $108.12. The firm has a market capitalization of $156.14 billion, a PE ratio of 25.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.